Top Markets
Coin of the day
Talaris Therapeutics, Inc. Talaris Therapeutics, Inc.

Talaris Therapeutics, Inc.

TALS
Classement en actions #21258
Talaris Therapeutics, Inc. is a cell therapy company operating in the United... Talaris Therapeutics, Inc. is a cell therapy company operating in the United States, currently in its late clinical development stages. Its mission involves pioneering an allogeneic hematopoietic stem cell transplantation strategy designed to revolutionize treatment paradigms for solid organ transplantation, severe autoimmune conditions, and significant non-malignant blood, immune, and metabolic disorders. The company's flagship product, FCR001, is an innovative allogeneic cell therapy presently in Phase II clinical trials for patients undergoing living donor kidney transplantation. Beyond this, Talaris Therapeutics is actively advancing FCR002 for use in deceased donor kidney transplants, investigating FCR001 for individuals with a severe form of scleroderma, and exploring its applicability for a range of other serious non-malignant blood, immune, or metabolic conditions. Founded in 1988, the company maintains its headquarters in Louisville, Kentucky.
Prix de l'action
$2.72
Dernière synchronisation: 2023-10-19
Capitalisation boursière
$111.47M
Changement (1 jour)
-0.73%
Changement (1 an)
0.00%
Pays
US
Échange Talaris Therapeutics, Inc. (TALS)

Catégorie

Ratio P/S pour Talaris Therapeutics, Inc. (TALS)
Ratio P/S au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Talaris Therapeutics, Inc., le ratio cours/ventes actuel (TTM) est 0. À la fin de 2026, le ratio P/S était de 0.
Historique du ratio P/S pour Talaris Therapeutics, Inc. de 2026 à 2026
Ratio P/S à la fin de chaque année
Année Ratio P/S Changez
Pas assez de données pour les dates fournies.
Ratio P/S pour des entreprises similaires ou concurrentes
Entreprise Ratio P/S Différence de Ratio P/S Pays
10.17 -
US
10.13 -
NL
11.28 -
US
2.95 -
AU
- -
CH